Global Blood Therapeutics
400 E Jamie Ct, Ste 101
South San Francisco, CA 94080-6230
(650) 741-7700|(650) 741-7719
Biotech and Pharmaceutical
Global Blood Therapeutics, Inc. is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and severe genetic disorders for which there are currently no cures available and only extremely limited therapeutic options. The company’s unique SHAPE Platform is enabling the discovery and development of small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits. Global Blood Therapeutics’ lead program focuses on Sickle Cell Disease (SCD), one of the earliest, rare genetic diseases to be defined on a molecular basis. It is caused by a single mutation that alters the oxygen-transport protein hemoglobin and results in the “sickling” – or change to a crescent shape – of red blood cells. Global Blood Therapeutics’ approach combines the most advanced approaches to computational biology and protein-ligand modeling with medicinal chemistry and empiric screening capabilities focused on allosteric modulation, while leveraging its team’s world-leading expertise in blood biology and proven success in drug discovery and development. Global Blood Therapeutics is a private company launched in 2012 by Third Rock Ventures with an experienced leadership team and renowned scientific founders.